Insider Selling: COMPASS Pathways plc (NASDAQ:CMPS) Major Shareholder Sells 2,660,000 Shares of Stock

COMPASS Pathways plc (NASDAQ:CMPS) major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total transaction of $16,093,000.00. Following the completion of the sale, the insider now directly owns 6,905,774 shares in the company, valued at approximately $41,779,932.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

COMPASS Pathways Stock Down 1.4 %

Shares of NASDAQ CMPS traded down $0.10 during trading on Friday, hitting $6.81. 236,067 shares of the company traded hands, compared to its average volume of 540,680. The business’s fifty day moving average is $7.16 and its 200 day moving average is $7.65. COMPASS Pathways plc has a fifty-two week low of $5.01 and a fifty-two week high of $12.75. The firm has a market capitalization of $465.74 million, a price-to-earnings ratio of -2.87 and a beta of 2.27. The company has a debt-to-equity ratio of 0.13, a quick ratio of 12.03 and a current ratio of 12.03.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, August 1st. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.03). During the same period in the prior year, the company earned ($0.62) EPS. Equities research analysts predict that COMPASS Pathways plc will post -2.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CMPS. HC Wainwright restated a “buy” rating and issued a $120.00 target price on shares of COMPASS Pathways in a report on Friday, August 23rd. Royal Bank of Canada restated an “outperform” rating and issued a $23.00 target price on shares of COMPASS Pathways in a report on Tuesday, September 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. Finally, Canaccord Genuity Group dropped their price objective on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, August 2nd. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $47.40.

Institutional Investors Weigh In On COMPASS Pathways

Several hedge funds and other institutional investors have recently made changes to their positions in CMPS. Quest Partners LLC bought a new stake in shares of COMPASS Pathways during the fourth quarter worth about $33,000. Blue Trust Inc. bought a new stake in shares of COMPASS Pathways during the second quarter worth about $81,000. Kennedy Capital Management LLC bought a new stake in shares of COMPASS Pathways during the first quarter worth about $139,000. Tidal Investments LLC increased its position in shares of COMPASS Pathways by 43.6% during the first quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock worth $159,000 after acquiring an additional 5,795 shares in the last quarter. Finally, Fore Capital LLC bought a new stake in shares of COMPASS Pathways during the second quarter worth about $181,000. 46.19% of the stock is owned by institutional investors.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.